Press release, 19.9.2023 at 10:15 a.m. (EEST)

Nightingale Health Plc (“Nightingale Health”), a pioneer in health risk detection and preventative health, will set up its UK laboratory in Porton Science Park in South Wiltshire.

Nightingale Health announced in January 2023 that it would open a laboratory in the United Kingdom to expand its commercial activities. The now-announced location for the laboratory has been awarded a UK Life Science Opportunity Zone status and is situated alongside established R&D institutions, including the Ministry of Defence’s Defence Science and Technology Laboratory (Dstl) and the UK Health Security Agency (UKHSA). The premises provide opportunities for collaboration and the sharing and promotion of innovation, expertise, and research with businesses based in the science park.

By making its proprietary blood analysis technology locally available in the United Kingdom, Nightingale Health aims to expand its business with the medical research industry and, eventually, the entire health ecosystem. Having a laboratory close to UK-based customers removes the necessity to transport blood samples to Finland, with sample handling, shipping, and analyses carried out domestically, enabling fast response times required in large-scale clinical use.

Nightingale Health expects the laboratory to be operational by the end of the calendar year 2023 and full-scale production capability to ramp up during the first quarter of 2024.

For further information, please contact:

Teemu Suna, CEO

About Nightingale Health

Nightingale Health is The Preventative Health Company. Staying healthy is one of the top priorities in human life. Our health has a profound impact on our quality of life, and it’s also strongly connected to the lives of those close to us. Nightingale Health enables prevention by combining the power of our in-house developed, advanced blood analysis technology with unprecedented access to global health repositories and world-leading medical research. With this combination, we go beyond the traditional healthcare and wellbeing tools: We provide the scientific connection to multiple health and disease outcomes and the ability to predict future healthy years.

Nightingale Health operates globally with a parent company in Finland and seven subsidiaries in countries such as Japan, the United States, Singapore, and the United Kingdom. Nightingale Health has customers in more than 25 countries in the healthcare and medical research sectors. The company’s technology is being used in many of the world’s leading health initiatives, such as the UK Biobank, and over 450 peer-reviewed publications validate the technology. The company’s Series B shares are listed on the First North Growth Market Finland marketplace. Read more: